The company's pharmaceutical business is organized into domestic and export sales with distribution spanned across 86 countries across Europe, Latin America, Asia, and North America. In Fiscals 2019, 2020, and 2021, sales from exports accounted for 70.96%, 71.85%, and 77.47% of the revenue of operations.
The Rs. 700 crore public offering of Supriya Lifesciences comprises a fresh issue of equity shares aggregating up to Rs. 200 crores and an offer for sale of equity shares aggregating up to Rs. 500 crores from selling shareholders.
|Financial Year Ended||Revenue (₹ Crores)||PAT (₹ Crores)||EPS (₹)|
|As of September 30, 2021||230.06||65.96||9.01|
|Issue Period||16th December to 20th December|
|Finalization of Allotment||23rd December 2021|
|Initiation of Refunds||24th December 2021|
|Credit of Shares||27th December 2021|
|Date of Listing||28th December 2021|
|Mandate end date||6th January 2022|
|Anchor Investors Lock-In End Date||27th January 2022|
How do I apply to the Supriya Lifescience Limited IPO?You can apply for the Supriya Lifescience Limited IPO using any supported UPI app by following two steps:
- Enter your bid on Console
- Accept UPI mandate on your phone
Where do I check the allotment status for Supriya Lifescience Limited IPO?You can check the allotment status for the Supriya Lifescience Limited IPO on the website of the Registrar and Transfer agent.
Alternatively, you can also check the allotment status on the NSE website.